Hormone Therapy + Radiation for Prostate Cancer
Trial Summary
The trial requires that you stop taking any testosterone replacement therapy and 5-alpha-reductase inhibitors at least 30 days before joining. Other medications are not specifically mentioned, so it's best to discuss your current medications with the trial team.
Research shows that using Bicalutamide (Casodex) 150 mg daily as an immediate treatment after radiotherapy significantly reduces the risk of prostate cancer progression by 37% compared to radiotherapy alone, indicating its effectiveness as an adjuvant therapy.
12345Bicalutamide, used in prostate cancer treatment, is generally well tolerated, but common side effects include breast pain and gynecomastia (enlarged breast tissue in men). In a study, adverse reactions occurred in about 61-65% of patients, but the treatment was still considered safe and effective.
24678This treatment combines hormone therapy with radiation, using drugs like bicalutamide (Casodex) to improve survival in high-risk prostate cancer patients. Unlike traditional castration therapies, bicalutamide offers a non-castration-based approach, potentially improving quality of life while effectively enhancing the effects of radiation therapy.
245910Eligibility Criteria
Men aged 18+ with unfavorable intermediate risk prostate cancer, specifically adenocarcinoma of the prostate, without prior treatments like radiotherapy or hormonal therapy to the pelvis. They must have a certain level of physical fitness (ECOG 0-2), adequate organ function, and no severe co-morbidities or high-risk features such as Gleason score 8-10 or metastatic disease.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Metastatic prostate cancer
- Locally advanced prostate cancer
- Metastatic prostate cancer
- Metastatic prostate cancer
- Locally advanced prostate cancer
- Metastatic prostate cancer
- Locally advanced prostate cancer
- Metastatic prostate cancer
- Locally advanced prostate cancer